Healthcare

Pliant Therapeutics Inc. concluded its 2025 fiscal year with marked operational improvements, highlighted by a significant reduction in its quarterly...

New clinical findings presented by Anavex Life Sciences have injected optimism into the biopharmaceutical firm's outlook. At a recent specialist...

Johnson & Johnson is currently bolstering its healthcare portfolio with significant operational progress. The company has achieved a key regulatory...

Positive results from its dialysis subsidiary, Fresenius Medical Care (FMC), are providing a significant boost to the parent company, Fresenius...

The Swiss medical technology firm Ypsomed is entering a decisive period, marked by the conclusion of a major capital initiative...

The Danish pharmaceutical giant Novo Nordisk finds itself navigating a complex landscape of regulatory challenges and strategic realignments. Recent developments...

The therapeutic landscape for chronic inflammatory bowel diseases (IBD) is on the cusp of a significant shift. For years, the...

Axil Brands is broadening its hearing technology offerings with the introduction of a new product designed for both professional and...

Facing the impending loss of patent protection for its blockbuster drug Stelara in 2025, Johnson & Johnson has been under...

As Sangamo Therapeutics advances its gene therapy candidate for Fabry disease, investor focus is split between imminent regulatory milestones and...